CYP 004
Alternative Names: CYP-004Latest Information Update: 29 Nov 2022
At a glance
- Originator Cynata Therapeutics
- Developer Cynata Therapeutics; University of Sydney
- Class Antirheumatics; Induced pluripotent stem cell therapies; Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Osteoarthritis
Most Recent Events
- 29 Nov 2022 CYP 004 is still in phase III trial for Osteoarthritis (In adults, In the elderly) in Australia (Intra-articular) (ACTRN12620000870954)
- 11 Nov 2020 Phase-III clinical trials in Osteoarthritis (In adults, In the elderly) in Australia (Intra-articular) (ACTRN12620000870954)
- 19 Jun 2020 Cynata Therapeutics plans a phase III trial for CYP 004 for Osteoarthritis in Australia